Current theranostics for neurodegenerative diseases (NDD) management are majorly symptomatic due to a lack of identification of early-stage biomarkers and the inefficiency of drugs to penetrate through the blood-brain barrier. Recently. the Neuro-nanotechnology interface has emerged as a potential strategy for diagnosis. monitoring. https://www.roneverhart.com/L-Homme-Ideal-Cologne-by-Guerlain/